nx-2127
nurix therapeutics
['leukemia', 'nx-2127', 'cll', 'nurix']
at the 64th annual meeting, we presented updates from the phase 1 trial of our first-in-class btk degrader, nx-2127, which is being studied in patients with chronic lymphocytic leukemia (#cll) and b-cell malignancies. learn more: #ash22 
Targeted #proteindegradation is only the beginning. Blazing a new path in medicine. $NRIX